Estados Unidos · Plataformas y datos · MarketBeat

X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia

Publicado por MarketBeat · Estados Unidos hace 1 h

X4 Pharmaceuticals (NASDAQ:XFOR) said it expects to complete enrollment in its pivotal Phase III 4WARD trial of mavorixafor for primary chronic neutropenia, or PCN, by the end of…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia

También te puede interesar

Amerisafe (AMSF) Q3 2026 Earnings Call Transcript

Microsoft to raise up to $25 billion in bond market as investors get pickier about AI debt binge

US proposes Venezuela elections for 2027, opposition leader Machado says

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Stock Market Today (Oct. 29, 2026): S&P 500 falls after Alphabet and Microsoft issue divergent earnings

NOW Stock On Track To Post Worst Single-Day Performance In Over 14 Years — Analysts See AI Upside Despite Slowing Growth

X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia

Compartir

También te puede interesar

Amerisafe (AMSF) Q3 2026 Earnings Call Transcript

Microsoft to raise up to $25 billion in bond market as investors get pickier about AI debt binge

US proposes Venezuela elections for 2027, opposition leader Machado says

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Stock Market Today (Oct. 29, 2026): S&P 500 falls after Alphabet and Microsoft issue divergent earnings

NOW Stock On Track To Post Worst Single-Day Performance In Over 14 Years — Analysts See AI Upside Despite Slowing Growth